PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative ColitisCarlsbad, CA, ...
Jessica Grembi, an assistant professor of pharmacology in Penn State's College of Agricultural Sciences, has received a ...
In any event, if you get caught foul (sometimes quite literally) of runner’s trots, try to take a break, slow down and ...
Ginger also has anti-inflammatory and antioxidant properties, which may help protect against gastrointestinal irritation ...
Patients who are prescribed antibiotics during immune checkpoint blockade therapy for solid tumors face a heightened risk for ...
PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing ...
Green tea contains caffeine and tannins, an antioxidant that can mess with iron absorption. So drinking it at certain times ...
PVP Labs, a biotechnology company advancing next-generation peptide-based therapeutics, today announced its participation in the JP Morgan Healthcare Conference 2026, where the company will engage ...
With smart DMPK strategies, cross-domain collaboration, and strong CDMO support, companies are pushing past the challenges of ...
Irish Examiner on MSN
Hungry for change: How will 2026 reshape the way we treat obesity?
From the King Kong of weight-loss jabs to the Godzilla of the category, the GLP-1 industry is undergoing big changes ...
3d
Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Coherus Oncology, Inc. ( CHRS) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 1:30 PM EST Good morning everyone. It's still the morning. Thanks for joining us for another session at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback